Our top priority is the health and safety of our community. Visit our COVID-19 information page to see how we're responding to the public health emergency.

    Support for you and your patients in one location.

    PATIENT SERVICES FOR DOJOLVI

    Have confidence in availability of DOJOLVI and access for your LC-FAOD patients

    As of November 2025, more than 700 patients have been prescribed DOJOLVI since its approval in June 2020.1

    Ultragenyx is committed to patients with rare diseases, which is why we created UltraCare Patient Services for DOJOLVI—your patients’ guide throughout their treatment journeys.

    Our UltraCare Guides have varied backgrounds, including as social workers, healthcare professionals, and patient advocates, and are ready to help patients gain and maintain access to DOJOLVI.



    UltraCare Guides help patients and their caregivers:

    insurance coverage icon
    Understand their
    insurance coverage
    patient support icon
    Utilize patient support program resources,
    including help with billing and coding
    financial assistance icon
    Find and navigate available financial assistance
    and patient assistance programs     that can help to
    cover co-pay and other out-of-pocket expenses
    personalized counseling icon
    Start and stay on DOJOLVI treatment through
    personalized counseling and education based
    on the recommendations, advice, and
    prescription of the patient’s healthcare team

    HELP YOUR PATIENTS ENROLL IN ULTRACARE

    Step 1: Complete the
    Start Form with your patient.
    Step 2: Fax the completed*
    Start Form to 1-415-723-7474.
    Contact our UltraCare Guides for additional support at 1-888-756-8657.

    Visit UltraCare

      

    *Please note that a completed form is required for patient enrollment.

    Download DOJOLVI materials

    Resources that may provide additional insight and support for you, your patients, and their families and caregivers

    Filter Resources:

    All

    For Healthcare Providers

    For Patients and Caregivers

    For Spanish-speaking Patients and Caregivers

    DOJOLVI Patient
    Case Studies

    When treating diverse LC-FAOD patient types, consider the patient case studies presented in this brochure.

    DOJOLVI® (triheptanoin) patient case studies
    Download | Share

    Back-to-School
    Checklist

    A tool to help your patients and their caregivers prepare for a discussion on managing DOJOLVI treatment during the upcoming school year

    DOJOLVI® (triheptanoin) Back-to-School Checklist
    Download | Share

    DOJOLVI
    Dosing Flashcard

    Important reminders to find your patient’s optimized DOJOLVI dose, as well as information on initiating and titrating DOJOLVI.

    DOJOLVI® (triheptanoin) Dosing Flashcard
    Download | Share

    DOJOLVI
    Start Form

    Complete the Start Form to prescribe DOJOLVI.

    DOJOLVI® (triheptanoin) Start Form
    Download | Share

    Annotated Guide for the
    DOJOLVI Start Form

    Instructions for how to complete the Start Form. This is a guide only. Do NOT complete and submit this document.

    Annotated Guide for the DOJOLVI® (triheptanoin) Start Form
    Download | Share

    Understanding DOJOLVI Dosing Brochure

    A resource that clarifies the individualized approach to DOJOLVI dosing and administration.

    Understanding DOJOLVI Dosing Guide
    Download | Share

    DOJOLVI Dosing Calculator
    Quick Start Guide

    Quick Start Guide designed to help you easily use the DOJOLVI Dosing Calculator.

    DOJOLVI® (triheptanoin) Dosing Calculator Quick Start Guide
    Download | Share

    DOJOLVI
    Patient Brochure

    Information for your patients about LC-FAOD, DOJOLVI, and support available to them

    DOJOLVI® (triheptanoin) Patient Brochure
    Download | Share

    DOJOLVI
    Dosing Guide

    Step-by-step instructions for storing, administering, and keeping track of DOJOLVI doses for your patients

    DOJOLVI® (triheptanoin) Dosing Guide
    Download | Share

    Materials Compatibility
    Reference

    A reference overview of materials that are compatible or incompatible to use with DOJOLVI

    DOJOLVI® (triheptanoin) Materials Compatibility Reference Download | Share

    Daily
    Dosing Tracker

    A tool your patients can use to keep track of DOJOLVI doses

    DOJOLVI® (triheptanoin) Daily Dosing Tracker
    Download | Share

    UltraCare Patient
    Resource Guide

    An overview of resources offered by UltraCare Patient Services

    UltraCare Patient Resource Guide
    Download | Share

    Descargar materiales de DOJOLVI

    DOJOLVI
    Folleto

    Información para sus pacientes sobre LC-FAOD, DOJOLVI y el apoyo disponible para ellos

    Folleto de DOJOLV(R)® (triheptanoin)
    Descargar | Compartir

    DOJOLVI
    Guía de dosificación

    Instrucciones paso a paso para almacenar, administrar y realizar un seguimiento de las dosis de DOJOLVI

    Guía de dosificación de DOJOLVI™ (triheptanoin)
    Descargar | Compartir

    Patient Stories

    Watch stories of patients and their caregivers navigating life with LC-FAOD and DOJOLVI.

    Photo of Janelle, Michael, and Hanna living with carnitine-acylcarnitine translocase (CACT) deficiency

    “We’re very fortunate we were able to get Hanna diagnosed and for the support from her healthcare team”

    — Mike, caregiver of Hanna

    Signature of Hanna Living with CACT, a type of LC-FAOD

    Watch Video

     

    “I really like working with my doctors as a team to actually understand what we’re going to do and why”

    — Alexandra, age 19

    Signature of Alexandra living with LCHAD, a type of LC-FAOD

    Watch Video

     
    Photo of Alexandra, living with long-chain 3-hydroxy-acyl-CoA dehydrogenase (LCHAD) deficiency
    Photo of Daniel living with carnitine palmitoyltransferase II (CPT II) definicency

    “Finding support has made it more manageable for me to live with CPT II”

    — Daniel, age 22

    Signature of Daniel Living with CPT II, a type of LC-FAOD

    Watch Video

     

    Patient Guidance for Dosing and Administering DOJOLVI

    Preparing DOJOLVI® (triheptanoin) Doses Videos

    These demo videos support your patients on how to use the dosing components to prepare a DOJOLVI dose.

     

    Watch Videos

      
    Ver videos en Español  

    Patient Guidance for Proper Mixing

    These videos demonstrate how to properly mix DOJOLVI into compatible semi-solid foods or liquids when preparing to take the medication orally.

    Do not administer DOJOLVI alone to avoid gastrointestinal upset. For complete information on the preparation and administration of DOJOLVI orally or enterally via a silicone or polyurethane feeding tube, please refer to Section 2.4 of the full Prescribing Information.

      Watch Videos  
    Mixing DOJOLVI® (triheptanoin) into food Video series

    VISIT LC-FAOD–RELATED WEBSITES

    Professional organizations

    Genetic Metabolic Dietitians International (GMDI) logo

    Genetic Metabolic Dietitians International (GMDI)

    A professional organization dedicated to nutrition therapy for genetic metabolic disorders

     
    Society for Inherited Metabolic Disorders (SIMD) logo

    Society for Inherited Metabolic Disorders (SIMD)

    A professional organization focused on research and advocacy for patients with inherited metabolic disorders

     

    Metabolic disease information and advocacy

    International Network for Fatty Acid Oxidation Research and Management (INFORM) logo

    International Network for Fatty Acid Oxidation Research and Management (INFORM)

    A scientific organization specifically dedicated to research and education about fatty acid oxidation disorders

     
    MitoAction logo

    MitoAction

    An advocacy organization working to educate and support patients with mitochondrial disease and their families

     

    Rare disease information and advocacy

    NIH Genetic and Rare Diseases Information Center (GARD) logo

    NIH Genetic and Rare Diseases Information Center (GARD)

    A center within the National Institutes of Health (NIH) that maintains a list of rare diseases and related terms to help people find reliable information about their disease

     
    Global Genes logo

    Global Genes

    An advocacy organization that provides support, education, and resources to the rare disease community

     
    National Organization for Rare Disorders (NORD) logo

    National Organization for Rare Disorders (NORD)

    A patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them

     
    Patient Advocacy at Ultragenyx Pharmaceutical logo

    Patient Advocacy at Ultragenyx Pharmaceutical

    A dedicated Ultragenyx team committed to providing rare disease education, resources, patient stories, and events

     

    Reference:

    1. Data on file. Ultragenyx Hub Data: Prescribed Patients. Ultragenyx Pharmaceutical Inc.; 2025.

    Stay Informed

    Sign up to receive more information and updates about DOJOLVI (triheptanoin).

    FOR US HEALTHCARE PROFESSIONALS

    *Required fields

    INDICATION

    DOJOLVI is a medium-chain triglyceride indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).

    IMPORTANT SAFETY INFORMATION

    WARNINGS AND PRECAUTIONS

    Feeding Tube Dysfunction

    • Feeding tube performance and functionality can degrade over time depending on usage and environmental conditions. In clinical trials, feeding tube dysfunction was reported in patients receiving triheptanoin. The contribution of DOJOLVI cannot be ruled out. Do not administer DOJOLVI in feeding tubes manufactured of polyvinyl chloride (PVC). Regularly monitor the feeding tube to ensure proper functioning and integrity.

    Intestinal Malabsorption in Patients with Pancreatic Insufficiency

    • Pancreatic enzymes hydrolyze triheptanoin and release heptanoate as medium-chain fatty acids in the small intestine. Low or absent pancreatic enzymes may result in reduced absorption of heptanoate subsequently leading to insufficient supplementation of medium-chain fatty acids. Avoid administration of DOJOLVI in patients with pancreatic insufficiency.

    ADVERSE REACTIONS

    Gastrointestinal (GI)

    • The most common GI-related adverse reactions reported in the pooled safety population of Studies 1 and 2 were abdominal pain (abdominal discomfort, abdominal distension, abdominal pain, abdominal pain upper, GI pain) [60%], diarrhea [44%], vomiting [44%], and nausea [14%].

    DRUG INTERACTIONS

    Pancreatic Lipase Inhibitors

    • Co-administration of triheptanoin with a pancreatic lipase inhibitor (e.g., orlistat) may reduce exposure to the triheptanoin metabolite, heptanoate, and reduce the clinical effect of triheptanoin. Avoid co-administration of DOJOLVI with pancreatic lipase inhibitors.

    USE IN SPECIFIC POPULATIONS

    Pregnancy and Lactation

    • There are no available data on triheptanoin use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There is a pregnancy safety study for DOJOLVI. If a patient becomes pregnant while receiving DOJOLVI, healthcare providers should report DOJOLVI exposure by calling Ultragenyx Pharmaceutical Inc. at 1-888-756-8657.
    • There are no data on the presence of triheptanoin or its metabolites in human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the clinical need for DOJOLVI and any potential adverse effect on the breastfed infant from DOJOLVI or from the underlying maternal condition.

    PATIENT COUNSELING INFORMATION

    • Instruct the patient or caregiver to read the FDA-approved patient labeling, which includes information on the appropriate oral or feeding tube preparation, administration, and storage.

    You may report side effects to Ultragenyx Pharmaceutical Inc. at 1-888-756-8657 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.


    Please see full Prescribing Information for a complete discussion of the risks associated with DOJOLVI.

    LESS -

    INDICATION

    DOJOLVI is a medium-chain triglyceride indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).

    IMPORTANT SAFETY INFORMATION

    WARNINGS AND PRECAUTIONS

    Feeding Tube Dysfunction

    • Feeding tube performance and functionality can degrade over time depending on usage and environmental conditions. In clinical trials, feeding tube dysfunction was reported in patients receiving triheptanoin. The contribution of DOJOLVI cannot be ruled out. Do not administer DOJOLVI in feeding tubes manufactured of polyvinyl chloride (PVC). Regularly monitor the feeding tube to ensure proper functioning and integrity.

    Intestinal Malabsorption in Patients with Pancreatic Insufficiency

    • Pancreatic enzymes hydrolyze triheptanoin and release heptanoate as medium-chain fatty acids in the small intestine. Low or absent pancreatic enzymes may result in reduced absorption of heptanoate subsequently leading to insufficient supplementation of medium-chain fatty acids. Avoid administration of DOJOLVI in patients with pancreatic insufficiency.

    ADVERSE REACTIONS

    Gastrointestinal (GI)

    • The most common GI-related adverse reactions reported in the pooled safety population of Studies 1 and 2 were abdominal pain (abdominal discomfort, abdominal distension, abdominal pain, abdominal pain upper, GI pain) [60%], diarrhea [44%], vomiting [44%], and nausea [14%].

    DRUG INTERACTIONS

    Pancreatic Lipase Inhibitors

    • Co-administration of triheptanoin with a pancreatic lipase inhibitor (e.g., orlistat) may reduce exposure to the triheptanoin metabolite, heptanoate, and reduce the clinical effect of triheptanoin. Avoid co-administration of DOJOLVI with pancreatic lipase inhibitors.

    USE IN SPECIFIC POPULATIONS

    Pregnancy and Lactation

    • There are no available data on triheptanoin use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There is a pregnancy safety study for DOJOLVI. If a patient becomes pregnant while receiving DOJOLVI, healthcare providers should report DOJOLVI exposure by calling Ultragenyx Pharmaceutical Inc. at 1-888-756-8657.
    • There are no data on the presence of triheptanoin or its metabolites in human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the clinical need for DOJOLVI and any potential adverse effect on the breastfed infant from DOJOLVI or from the underlying maternal condition.

    PATIENT COUNSELING INFORMATION

    • Instruct the patient or caregiver to read the FDA-approved patient labeling, which includes information on the appropriate oral or feeding tube preparation, administration, and storage.

    You may report side effects to Ultragenyx Pharmaceutical Inc. at 1-888-756-8657 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.


    Please see full Prescribing Information for a complete discussion of the risks associated with DOJOLVI.

    MORE +